DekaLux-BioTech CF |
Performance History | 31/03/2024 |
Growth of 1,000 (EUR) |
Fund | 14.9 | 7.3 | -7.2 | 1.3 | 2.6 | |
+/-Cat | -4.3 | 10.3 | 5.6 | 0.3 | -1.1 | |
+/-Idx | -10.9 | 0.3 | -4.2 | -8.6 | -7.4 | |
Category: Sector Equity Biotechnology | ||||||
Benchmarks: Morningstar Gbl Biotechnolo... |
Key Stats | ||
NAV 19/04/2024 | EUR 514.89 | |
Day Change | -0.80% | |
Morningstar Category™ | Sector Equity Biotechnology | |
ISIN | LU0348461467 | |
Fund Size (Mil) - | - | |
Share Class Size (Mil) 19/04/2024 | EUR 159.12 | |
Max Initial Charge | 3.75% | |
Ongoing Charge 19/01/2024 | 1.50% |
Investment Objective: DekaLux-BioTech CF |
N/A |
Returns | ||||||||||||||||
|
Management | ||
Manager Name Start Date | ||
Not Disclosed 02/06/2008 | ||
Inception Date 02/06/2008 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR EUR | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for DekaLux-BioTech CF | 31/12/2023 |
|
|
Top 5 Holdings | Sector | % |
Vertex Pharmaceuticals Inc | Healthcare | 8.88 |
Regeneron Pharmaceuticals Inc | Healthcare | 7.17 |
Amgen Inc | Healthcare | 6.96 |
Gilead Sciences Inc | Healthcare | 6.60 |
Alnylam Pharmaceuticals Inc | Healthcare | 3.08 |
Increase Decrease New since last portfolio | ||
DekaLux-BioTech CF |